This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Scientific publications
Scientific articles authored by Novo Nordisk
The information you can search here is retrieved via the database Current Contents®, covering 95% of publications within the life science area. Only articles authored by at least one researcher from Novo Nordisk are included in the search results. The database provides easy access to tables of contents, abstracts, bibliographic information, and abstracts from the most recently published issues of leading scholarly journals.
Journal |
Author | Year | |
| Biochemistry Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec |
Steensgaard DB ; Schluckebier G ; Strauss HM ; Norrman M ; Thomsen JK ; Friderichsen AV ; Havelund S ; Jonassen I | 2013 | |
| Diabetes Care The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes |
Meneghini L ; Atkin SL ; Gough SCL ; Raz I ; Blonde L ; Shestakova M ; Bain S ; Johansen T ; Begtrup K ; Birkeland KI | 2013 | |
| Diabetes Obesity and Metabolism Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials |
Ratner RE ; Gough SCL ; Mathieu C ; Del Prato S ; Bode B ; Mersebach H ; Endahl L ; Zinman B | 2013 | |
| Diabetic Medicine Insulin degludec improves health-related quality of life (SF- 36 (R)) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials |
Freemantle N ; Meneghini L ; Christensen T ; Wolden ML ; Jendle J ; Ratner R | 2013 | |
| Journal of Clinical Endocrinology and Metabolism Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes ( BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension |
Mathieu C ; Hollander P ; Miranda-Palma B ; Cooper J ; Franek E ; Russell-Jones D ; Larsen J ; Tamer SC ; Bain SC | 2013 | |
| Diabetes Care Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in PatientsWith Type 1 Diabetes A 26-week, phase 3, randomized, open-label, treat-to-target trial |
Hirsch IB ; Bode B ; Courreges JP ; Dykiel P ; Franek E ; Hermansen K ; King A ; Mersebach H ; Davies M | 2012 | |
| Diabetes Care Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes A 1-year, randomized, treat-to- target trial (BEGIN Once Long) |
Zinman B ; Philis-Tsimikas A ; Cariou B ; Handelsman Y ; Rodbard HW ; Johansen T ; Endahl L ; Mathieu C | 2012 | |
| Diabetes Obesity and Metabolism Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes |
Heise T ; Hermanski L ; Nosek L ; Feldman A ; Rasmussen S ; Haahr H | 2012 | |
| Diabetes Obesity and Metabolism Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes |
Heise T ; Nosek L ; Bottcher SG ; Hastrup H ; Haahr H | 2012 | |
| Diabetic Medicine Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes |
Home PD ; Meneghini L ; Wendisch U ; Ratner RE ; Johansen T ; Christensen TE ; Jendle J ; Roberts AP ; Birkeland KI | 2012 | |
| European Journal of Endocrinology Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial |
Niskanen L ; Leiter LA ; Franek E ; Weng JP ; Damci T ; Munoz-Torres M ; Donnet JP ; Endahl L ; Skjoth TV ; Vaag A | 2012 | |
| Lancet Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non- inferiority trial |
Heller S ; Buse J ; Fisher M ; Garg S ; Marre M ; Merker L ; Renard E ; Russell-Jones D ; Philotheou A ; Francisco AMO ; Pei HL ; Bode B | 2012 | |
| Lancet Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non- inferiority trial |
Garber AJ ; King AB ; Del Prato S ; Sreenan S ; Balci MK ; Munoz-Torres M ; Rosenstock J ; Endahl LA ; Francisco AMO ; Hollander P | 2012 | |
| Pharmaceutical Research Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin |
Jonassen I ; Havelund S ; Hoeg-Jensen T ; Steensgaard DB ; Wahlund PO ; Ribel U | 2012 | |
| Diabetes Care Insulin Degludec in Type 1 Diabetes A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine |
Birkeland KI ; Home PD ; Wendisch U ; Ratner RE ; Johansen T ; Endahl LA ; Lyby K ; Jendle JH ; Roberts AP ; DeVries JH ; Meneghini LF | 2011 | |
| Diabetes Care A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naive People With Type 2 Diabetes A randomized, controlled trial |
Heise T ; Tack CJ ; Cuddihy R ; Davidson J ; Gouet D ; Liebl A ; Romero E ; Mersebach H ; Dykiel P ; Jorde R | 2011 | |
| Lancet Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial |
Zinman B ; Fulcher G ; Rao PV ; Thomas N ; Endahl LA ; Johansen T ; Lindh R ; Lewin A ; Rosenstock J ; Pinget M ; Mathieu C | 2011 | |
 |
|||
